NEW YORK (GenomeWeb News) – GeneGo said today that the Scripps Translational Science Institute has become the first member of a consortium that the company is building to develop a systems biology software and database platform for cardiovascular diseases.
The company plans to add other members from the pharmaceutical and academic communities to the MetaMiner Cardiac Consortium. The members of the consortium will have a say in what cardiac-specific ontologies and pathway maps the company will incorporate into the MetaMiner product.
Scripps and any future consortium members, in return, will have free access to the product GeneGo develops. The company plans to put the product on the market six to 12 months after the consortium members have access to it, Julie Bryant, GeneGo’s VP of business development and marketing, told GenomeWeb Daily News today.
The company recently released a similar MetaMiner software and database platform for cystic fibrosis.
Cardiac Consortium memberships last for three years, and the company should be ready to release a MetaMiner Cardiac product within one to two years, Bryant said.